Johnson & Johnson's flu drug succeeds in mid-stage trial

June 14 (Reuters) - Johnson & Johnson said on Wednesday its experimental flu drug significantly reduced viral load compared to a placebo in a mid-stage study of patients with a type of influenza.

Study data also showed that adding J&J's drug, pimodivir, to a widely-used flu treatment called oseltamivir resulted in a significantly lower viral load in some patients, compared to those who received pimodivir alone. (Reporting by Divya Grover in Bengaluru; Editing by Sai Sachin Ravikumar)